Clinical Trial Update: Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating stereotactic body radiotherapy followed by ipilimumab in stage IV melanoma was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Skin Melanoma

Drugs mentioned

• Stereotactic Body Radiotherapy
• ipilimumab (ipilimumab)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2020-02-13